MT-TP and hepatocellular carcinoma: However, although these early studies showed that, while MTTP inhibition effectively lowered plasma cholesterol, it significantly increased hepatic lipid and liver damage, which elevated the risk of NAFLD and HCC (Chang et al., 2002; Cuchel et al., 2007; Samaha et al., 2008).